Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab and Brentuximab Vedotin in CTCL and MF
NCT05414500Phase 1Suspended
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mogamulizumab and brentuximab vedotin in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF), sponsored by University of Alabama at Birmingham. Primary endpoints: Rates of Adverse Events at 1 year and Rates of Serious Adverse Events at 28 days. Started May 2023; status: suspended.
02
Drugs
mogamulizumabbrentuximab vedotin
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT05414500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414500.